Atlas Trials

Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

3 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

RecordFirmDate
A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation (NCT04691648)Astellas Pharma Korea, Inc.2022-06-17
A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) (NCT03730012)Astellas Pharma Global Development, Inc.2019-06-19
A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy (NCT02752035)Astellas Pharma Global Development, Inc.2016-08-01

Track Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation automatically

Every clearance here is in the API, with alerts when new ones post.